Stock Events

Novo Nordisk 

$140.7
5203
+$2.17+1.57% Friday 15:30

統計

當日最高
-
當日最低
-
52週最高
-
52週最低
-
成交量
-
平均成交量
-
市值
-
市盈率
-
股息收益率
1.32%
股息
1.86

即將到來

股息

1.32%股息收益率
10年增長
8.39%
5年增長率
8.67%
3年增長率
8.07%
1年增長率
-9.64%

收益

2May確認
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
0
2.93
5.85
8.78
預期每股收益
N/A
實際每股收益
5.68

人們還關注

此列表基於在 Stock Events 上關注 0TDD.LSE 的人的關注列表。這不是投資建議。

競爭者

這個列表是基於最近市場事件的分析。這不是投資建議。

關於

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Show more...
首席執行官
Mr. Lars Fruergaard Jorgensen
員工
52696
國家
Denmark
ISIN
US6701002056
WKN
000866931

上市公司